Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  aggressive, contiguous stage II adult non-Hodgkin lymphoma
Stage/Subtype:  aggressive, contiguous stage II adult non-Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 85 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-008, NCI-2015-00708, NCT01996865
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B3281006, NCI-2015-00476, 2014-000132-41, REFLECTIONS, NCT02213263
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CT-P10 3.4, NCI-2016-00728, NCT02260804
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 80
Trial IDs: CC-5013-DLC-002, NCI-2015-00282, 2013-004054-21, NCT02285062
Lenalidomide, Rituximab, Cyclophosphamide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Diffuse Large Cell or Grade 3A/B Follicular B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC078E, NCI-2009-01196, Celgene #RV-NHL-PI-0325, RV-NHL-PI-0325, MAYO-MC078E, NCT00670358
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Romidepsin and Lenalidomide in Treating Patients with Relapsed or Refractory Lymphoma or Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-170, NCI-2013-00005, NCT01755975
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 74
Trial IDs: I 240813, NCI-2013-01784, NCT01959698
A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO27878, NCI-2016-00590, NCT02055820
Sheddase Inhibitor INCB007839 and Rituximab after Autologous Hematopoietic Stem Cell Transplant in Treating Patients with Diffuse Large B Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013LS081, NCI-2014-00243, 1404M49823, HM2013-24, NCT02141451
Lenalidomide and Combination Chemotherapy in Treating Patients with MYC-Associated B-Cell Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-1406, NCI-2014-01581, IRB13-1406, IRB13-1406-CR001, NCT02213913
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: DV3-LYM-01, NCI-2014-02214, NCT02266147
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-LY-001, NCI-2015-00533, NCT02328014
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-19, NCI-2015-01462, NCT02391545
Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IMDZ-G142, NCI-2015-01368, NCT02501473
Lenalidomide, Obinutuzumab, and Combination Chemotherapy in Treating Patients with Stage I-IV Diffuse Large B Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0069, NCI-2015-01517, NCT02529852
Start Over